Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.


HHS - 1483 - National Cancer Institute Board of Scientific Advisors - Authorized by Law
Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameNational Cancer Institute Board of Scientific AdvisorsAgency NameDepartment of Health and Human Services
Fiscal Year2020Committee Number1483
Original Establishment Date11/20/1985Committee StatusChartered
Actual Termination Date Committee URLhttp://deainfo.nci.nih.gov/advisory/bsa/bsa.htm
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*35
Current Charter Date10/8/2019Designated Fed Officer Position Title*DIRECTOR, DIVISION OF EXTRAMURAL ACTIVITIES, NCI
Date Of Renewal Charter10/8/2021Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*PAULETTE
Exempt From Renewal*NoDesignated Federal Officer Middle NameS.
Specific Termination AuthorityDesignated Federal Officer Last Name*GRAY
Establishment Authority*Authorized by LawDesignated Federal Officer SuffixPH.D.
Specific Establishment Authority*42 U.S.C. 285a-2(b)(7)Designated Federal Officer Phone*240-276-6340
Effective Date Of Authority*11/20/1985Designated Federal Officer Fax*240-276-7815
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*grayp@mail.nih.gov
Committee Type*Continuing
Presidential*No
Committee Function*Scientific Technical Program Advisory Board
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The Board is composed of members who are distinguished scientists from outside the NCI and representatives from the advocacy community. The Board provides scientific advice on a wide variety of matters concerning scientific program policy, progress and future direction of the extramural research programs, and concept review of extramural program initiatives. This includes the evaluation of NCI awarded grants, oversight of concept review of cooperative agreements and contracts initiatives and those activities which it considers meritorious and consistent with the Institute’s programs. The advisory role of the Board is scientific and does not include deliberation on matters of public policy. In 2020, the BSA was presented reports on various topics related to cancer research in general as well as legislative matters. BSA members provided insights regarding a final report from the BSA ad hoc Working Group in Support of the Childhood Cancer Data Initiative. As a result, they approved several recommendations addressing the following broad thematic areas in pediatric and adolescent and young adult (AYA) cancer research: (1) Types of Data for Collection/Aggregation; (2) Landscape of Pediatric/AYA Cancer Research Data and Needs Analysis; (3) Potential Barriers to Progress; (4) Generating New Data; (5) Research versus Clinical Data; (6) Patients, Families, and Advocates; and (7) Potential Opportunities for Transformative Discoveries. The Board reviewed and deliberated on request for application (RFA) concepts covering a wide variety of topics including the following: Research to Reduce Morbidity and Improve Care for Pediatric and Adolescent and Young Adults (AYA) Cancer Survivors (Clinical Trial Optional) (New RFA); Metastasis Research Network (New RFA/Coop. Agr.); Addressing Gaps in Knowledge Utilizing Cancer Survivor Cohort Studies (No Clinical Trial Options) (New RFA); Strengthening Institutional Capacity to Conduct Global Cancer Research (New RFA); Glioblastoma Therapeutics Network (New RFA); Tobacco Cessation, HIV, and Comorbidities in Low- and Middle-Income Countries (New RFA); Aging, Cancer-Initiating Cells, and Cancer Progression (New RFA/Coop. Agr.); Cancer Intervention and Surveillance Modeling Network (CISNET) Incubator Program for New Cancer Sites (New RFA/Coop. Agr.); Pediatric Preclinical Testing Public-Private Partnership (PPTP3) (Re-issue RFA/ Coop. Agr.); International Agency for Research on Cancer (IARC) Monographs Program (Re-Issue RFA/Limited Competition); 3D Technologies to Accelerate Human Tumor Atlas Network (HTAN) Atlas Building Efforts (HTAN #1) (New RFA/Coop. Agr.); Cancer MoonshotSM Data Visualization Methods and Tools Development (R33) (NET #1) (New RFA); New Cohorts to Assess Environmental Exposures and Cancer Risk (New RFA); Childhood Cancer Survivorship Study (CCSS) (Re-issue RFA); Collaborative Approaches to Engineer Biology for Cancer Applications (New RFA/Coop. Agr.); The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) (Re-issue RFA); Small Business Transition Grant (New RFA); and The Cancer Genome Atlas (TCGA) Network: TCGA Genome Characterization Center (GCC) and TCGA Genome Data Analysis Center (GDAC) (Re-Issue RFA).
How is membership balanced?*The Board consists of up to 35 members, including the Chair, appointed by the Director, NCI, from authorities knowledgeable in the fields of laboratory, clinical and biometric research, clinical cancer treatment, cancer etiology, and cancer prevention and control, with emphasis on training and experience in the various disciplines and fields related to scientific areas relevant to carcinogenesis, cancer biology and diagnosis, cancer center administration, medicine, radiological and surgical oncology, cancer chemotherapy, cancer epidemiology, cancer prevention and control, cancer education, cancer information services, community outreach, biological, chemical and physical carcinogenesis, DNA repair and effects, tumor biology and immunology, humoral and cellular immunity, hematopoiesis, cell differentiation and transformation, oncogenes and growth factors, molecular and structural biology and genetic regulation, viral oncology, vaccine development, transplantation, chemotherapy, clinical trial design, management and evaluation, pharmacology, drug development and developmental therapeutics, genetic and immunotherapies, pathology, diagnostic research and cytogenetics, biological response modifiers, imaging, nutrition, survey research, epidemiology, biostatistics, rehabilitation, psychology and behavioral medicine, public health and community oncology, quality of life, pain management, cancer detection and diagnosis, cancer treatment and restorative care, dentistry, nursing, public health, nutrition, education of health professionals, medical oncology, surgery, radiotherapy, gynecologic oncology, pediatric oncology, pathology, and biostatistics. Geographical, gender, ethnic and racial considerations are addressed in selecting members for appointment to the Board.
How frequent & relevant are cmte mtgs?*Meetings are held not less than three times a year. The committee met four times during this reporting period. The Board met jointly with the National Cancer Advisory Board for the December 2019, and virtually for the April 2020 and virtual June 2020 meetings. The Board also met virtually in May 2020. The Board’s deliberations are an indispensable part of the review of a very large part of the Institute’s extramural program, as well as concept review of request for applications (RFAs), program announcements with special receipt, referral, and review (PARs), and research and development (R&D) requests for proposals(RFP) contract initiatives in the extramural research program. According to the Board’s charter, approximately three formal meetings are held each year for the review of the extramural programs and concept review of RFAs; cooperative agreements; and, research and development RFPs. The BSA ad hoc Working Group on Prevention met on 23 October and 31 October 2019. The BSA ad hoc Working Group in Support of the Childhood Cancer Data Initiative met virtually on 25 November 2019, 17 January 2020, 27 March 2020, 31 March 2020, 12 May 2020, 28 May 2020, and 2 June 2020.
Why advice can't be obtained elsewhere?*This Board is composed of recognized biomedical research authorities from outside the NIH in order to secure unbiased and objective evaluations of extramural research programs. Their recommendations are invaluable because the complex nature of the research requires a unique balance and breadth of expertise not available at NIH or from other established sources.
Why close or partially close meetings?N/A
Recommendation RemarksMembers: The terms for Graham Colditz, Carol Ferrans, James Lacey, Martine Roussel, Victoria Seewaldt, Kevin Shannon, and Eileen White have changed due to administrative extensions. As such, their term of service end dates are different than what was reported on the FY19 ACR. The terms for Kenneth Anderson, Dafna Bar Sagi, Graham Colditz, Martine Roussel, Kevin Shannon, and Eileen White are longer than the charter allows due to their reappointment to the BSA given their specific scientific expertise and the need to assure continuity in the functions of the BSA and the deliberation of issues brought before the Board.

The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute.

The Data Sharing Opportunities in Childhood, Adolescent and Young Adult (AYA) Cancer Research for the National Cancer Institute - Report of the Board of Scientific Advisors on the Childhood Cancer Data Initiative (CCDI) working group was deliberated on by the NCI Board of Scientific Advisors.
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*Yes
Outcome Trust In GovernmentNoAction Reallocate ResourcesYes
Outcome Major Policy ChangesNoAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherNo
Outcome Increased Customer SatisfactionNoAction CommentPriorities are reorganized based on motions made by Board members regarding RFA and RFP concepts. Resources are allocated based on approved concepts.
Outcome Implement Laws/Reg RequirementsNoGrants Review*No
Outcome OtherYesNumber Of Grants Reviewed0
Outcome CommentBased on the approval of the various RFA and RFP concepts, significant advances in cancer research could lead to new treatments, prevention and control initiatives, and behavioral modifications and cures for different cancer sites. Another outcome is the annual posting of the RFA Report.Number Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentMeetings are held not less than three times a year. The committee met three times during this reporting period. The Board met jointly with the National Cancer Advisory Board for the December 2018 and June 2019 meetings. The Board also met in March 2019. Additionally, RFA and RFP concepts are reviewed annually to determine the need for reissuance based on the Board recommendations. Ad hoc Subcommittee and/or working group meetings are held to gather information. Recommendations are reported back at a full board meeting where advice is given to the Institute. The BSA supports the Institute in meeting its mission and as a result even though it can’t be calculated, there are substantive savings.Grants Review CommentNA
Number Of Recommendations*370Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentIn addition to general recommendations, specific recommendations by the committee include: 1. A motion to concur on establishing the Cancer Grand Challenges Initiative, a new NCI program in collaboration with Cancer Research United Kingdom (CRUK), was approved unanimously. 2. A motion to accept the report of the 24 May 2019 BSA ad hoc Subcommittee on HIV and AIDS Malignancy meeting was approved unanimously. 3. A motion to approve the Division of Cancer Control and Population Sciences’ (DCCPS) new Request for Applications (RFA) entitled “Research to Reduce Morbidity and Improve Care for Pediatric and Adolescent and Young Adults (AYA) Cancer Survivors (Clinical Trial Optional)” was approved unanimously. 4. A motion to approve the Division of Cancer Biology’s (DCB) new RFA/Cooperative Agreement (Coop. Agr.) entitled “Metastasis Research Network” was approved unanimously. 5. A motion to approve the DCCPS’ new RFA entitled “Addressing Gaps in Knowledge Utilizing Cancer Survivor Cohort Studies (No Clinical Trial Options)” with the inclusion of recurrence studies was approved unanimously. 6. A motion to approve the Office of the Director’s (OD) new RFA entitled “Strengthening Institutional Capacity to Conduct Global Cancer Research” was approved unanimously. 7. A motion to approve the Division of Cancer Prevention’s (DCP) new Request for Proposal (RFP) entitled “Addressing a ‘Last Mile’ Problem in Cervical Cancer Screening” was approved unanimously. 8. A motion to approve the Division of Cancer Treatment and Diagnosis’ (DCTD) new Program Announcement with special Receipt, Referral, and/or Review (PAR) entitled “Towards Translation of Cancer Nanotechnology Intervention (R01) (Clinical Trial Not Allowed)” was approved unanimously. 9. A motion to concur on the re-issuance of the DCTD’s PAR entitled “Academic–Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01) (Clinical Trial Optional)” was approved unanimously. 10. A motion to approve the DCTD’s new RFA entitled “Glioblastoma Therapeutics Network” was approved unanimously. 11. A motion to approve the DCCPS’ new RFA entitled “Tobacco Cessation, HIV, and Comorbidities in Low- and Middle-Income Countries” was approved unanimously. 12. A motion to approve the DCB’s new RFA/Coop. Agr. entitled “Aging, Cancer-Initiating Cells, and Cancer Progression” was approved with 24 ayes, zero nays, and 1 abstention. 13. A motion to approve the OD’s new RFP entitled “SBIR Contract Topics” was approved unanimously. 14. A motion to approve the OD’s new RFP entitled “SBIR Innovative Concept Award to Develop Transformational Solutions Focused on Prevention, Detection, Treatment, and Research in Pediatric Cancers and Rare Cancers” was approved with 24 ayes, zero nays, and 1 abstention. 15. A motion to approve the DCCPS’s new RFA/Coop. Agr. entitled “Cancer Intervention and Surveillance Modeling Network (CISNET) Incubator Program for New Cancer Sites” was approved unanimously. 16. A motion to concur on the re-issuance of the DCTD’s RFA/ Coop. Agr. entitled “Pediatric Preclinical Testing Public-Private Partnership (PPTP3)” was approved unanimously. 17. A motion to concur on the re-issuance of the DCB’s RFA/Limited Competition entitled “International Agency for Research on Cancer (IARC) Monographs Program” was approved unanimously. 18. A motion to defer the DCP’s RFP entitled “Developing a New Low-Dose CT Image Library to Facilitate AI Development for Lung Cancer Screening” was approved with 23 ayes, 2 nays, and zero abstentions. 19. A motion to approve the DCCPS’s PAR entitled “Social and Behavioral Intervention Research to Address Modifiable Risk Factors for Cancer in Rural Populations” was approved unanimously, with the change in scope from a PAR to an RFA. 20. A motion to approve the OD’s new RFA/Coop. Agr. entitled “3D Technologies to Accelerate Human Tumor Atlas Network (HTAN) Atlas Building Efforts (HTAN #1)” was approved unanimously. 21. A motion to approve the OD’s new RFA entitled “Cancer MoonshotSM Data Visualization Methods and Tools Development (R33) (NET #1)” was approved unanimously. 22. A motion to concur on establishing the NCI COVID-19 Serological Sciences Network was approved unanimously. 23. A motion to accept the final report of the BSA ad hoc Working Group to Support the Childhood Cancer Data Initiative was approved unanimously. 24. A motion to approve the DCCPS’ new RFA entitled “New Cohorts to Assess Environmental Exposures and Cancer Risk” was approved with 22 ayes, 1 nay, and 1 abstention. 25. A motion to concur on the re-issuance of the DCTD’s RFA entitled “Childhood Cancer Survivorship Study (CCSS)” was approved with 22 ayes, zero nays, and 2 abstentions. 26. A motion to approve the DCTD’s new RFP entitled “Clinical Trials Monitoring Service (CTMS)” was approved unanimously. 27. A motion to approve the OD’s new RFA/Coop. Agr. entitled “Collaborative Approaches to Engineer Biology for Cancer Applications” was approved unanimously. 28. A motion to concur on the re-issuance of the OD’s RFA entitled “The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)” was approved unanimously. 29. A motion to approve the OD’s new RFA entitled “Small Business Transition Grant” was approved unanimously. 30. A motion to concur on the re-issuance of the OD’s RFA entitled “The Cancer Genome Atlas (TCGA) Network: TCGA Genome Characterization Center (GCC) and TCGA Genome Data Analysis Center (GDAC)” was approved unanimously. 31. A motion to concur on the re-issuance of 12 PARs was approved unanimously. 32. A motion to approve the OD’s new PAR entitled “Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection In Vivo” was approved unanimously.Access Agency WebsiteYes
% of Recs Fully Implemented*90.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentThe percentage of recommendations implemented as stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.govAccess GSA FACA WebsiteYes
% of Recs Partially Implemented*10.00%Access PublicationsYes
% of Recs Partially Implemented CommentThe percentage of recommendations implemented stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.Access OtherYes
Agency Feedback*YesAccess CommentInformation on the BSA can be found at the NCI Division of Extramural Activities: Advisory Boards, Committees and Review Groups website at http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm. Each NCI committee’s charter, minutes, agenda, roster, future meeting dates, meeting PowerPoint presentations and reports is located here. Additionally, the public may view the BSA meetings (both live and on demand) via the NIH Videocast at the following website: http://videocast.nih.gov/.
Agency Feedback Comment*The NCI Director’s Report is presented at each Board meeting. Each NCI Division gives an update regarding progress of approved RFAs, cooperative agreements and contract concepts. Also, the Annual RFA Report is presented at each November/December Joint BSA/National Cancer Advisory Board meeting to show RFAs published and reviewed. A list of action items are assigned to individual NCI staff with specific time frames with deadlines.Narrative Description*The goal of NIH research is to acquire new knowledge to help prevent, detect, diagnose, and treat disease and disability, from the rarest genetic disorder to the common cold. The NIH mission is to uncover new knowledge that will lead to better health for everyone. NIH works toward that mission by the National Cancer Institute Board of Scientific Advisor’s (BSA). The BSA is composed of distinguished scientists from outside the NCI and representatives from the advocacy community. The BSA provides scientific advice on a wide variety of matters concerning scientific program policy, reviews the progress and future direction of the extramural research programs, and concept review of extramural program initiatives. This includes the oversight of research and development, concept review of request for applications, cooperative agreements, initiatives and other programmatic activities. The advisory role of the BSA is scientific and does not include deliberation on matters of public policy. The BSA represents the scientific community's voice in the extramural science the NCI supports. As such, the Board advises the NCI leadership on the progress and future direction of the Institute's Extramural Research Program. The Board evaluates NCI extramural programs, and reviews ideas for new research opportunities and solicitations to ensure that a concept is meritorious and consistent with the Institute's mission. Additionally, the BSA believes it is important to interact with and receive feedback from the clinical, population science, and laboratory research communities affected by NCI policies. The BSA’s deliberations are an indispensable part of the review of a very large part of the Institute's extramural program.
Hide Section - COSTS

COSTS

Payments to Non-Federal Members*$22,400.00Est Payments to Non-Fed Members Next FY*$22,400.00
Payments to Federal Members* Est. Payments to Fed Members Next FY* 
Payments to Federal Staff*$52,793.00Estimated Payments to Federal Staff*$57,124.00
Payments to Consultants*$2,600.00Est. Payments to Consultants Next FY*$2,600.00
Travel Reimb. For Non-Federal Members*$21,570.00Est Travel Reimb Non-Fed Members nextFY*$21,704.00
Travel Reimb. For Federal Members* Est Travel Reimb For Fed Members* 
Travel Reimb. For Federal Staff* Est. Travel Reimb to Fed Staff Next FY* 
Travel Reimb. For Consultants*$1,532.00Est Travel Reimb to Consultants Next FY*$1,542.00
Other Costs$104,161.00Est. Other Costs Next FY*$105,202.00
Total Costs$205,056.00Est. Total Next FY*$210,572.00
Federal Staff Support (FTE)*0.40Est. Fed Staff Support Next FY*0.40
Cost RemarksEst Cost Remarks
Hide Section - Interest Areas

Interest Areas

Category
Area
Health
Treatment
Medicine
Diseases
Health and Health Research
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-036569National Cancer Institute Board of Scientific Advisors2019
 COM-034777National Cancer Institute Board of Scientific Advisors2018
 COM-001923National Cancer Institute Board of Scientific Advisors2017
 COM-002258National Cancer Institute Board of Scientific Advisors2016
 COM-004079National Cancer Institute Board of Scientific Advisors2015
 COM-004408National Cancer Institute Board of Scientific Advisors2014
 COM-006156National Cancer Institute Board of Scientific Advisors2013
 COM-006867National Cancer Institute Board of Scientific Advisors2012
 COM-008324National Cancer Institute Board of Scientific Advisors2011
 COM-009069National Cancer Institute Board of Scientific Advisors2010
 COM-010116National Cancer Institute Board of Scientific Advisors2009
 COM-011002National Cancer Institute Board of Scientific Advisors2008
 COM-012119National Cancer Institute Board of Scientific Advisors2007
 COM-012487National Cancer Institute Board of Scientific Advisors2006
 COM-013962National Cancer Institute Board of Scientific Advisors2005
 COM-014543National Cancer Institute Board of Scientific Advisors2004
 COM-016033National Cancer Institute Board of Scientific Advisors2003
 COM-016593National Cancer Institute Board of Scientific Advisors2002
 COM-017634National Cancer Institute Board of Scientific Advisors2001
 COM-018354National Cancer Institute Board of Scientific Advisors2000
 COM-019571National Cancer Institute Board of Scientific Advisors1999
 COM-020365National Cancer Institute Board of Scientific Advisors1998
 COM-021711National Cancer Institute Board of Scientific Advisors1997